HQL - Tekla Life Sciences Investors

NYSE - Nasdaq Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
9/29/2018
9/29/2017
Total Revenue
10,462
29,822
69,811
Cost of Revenue
-
-
-
Gross Profit
-
-
-
Operating Expenses
Research Development
-
-
-
Selling General and Administrative
888
881
992
Total Operating Expenses
1,157
1,157
1,256
Operating Income or Loss
-
-
-
Interest Expense
-
-
-
Total Other Income/Expenses Net
-
-
-
Income Before Tax
9,305
28,664
68,556
Income Tax Expense
-
-
-
Income from Continuing Operations
9,305
28,664
68,556
Net Income
9,305
28,664
68,556
Net Income available to common shareholders
9,305
28,664
68,556
Reported EPS
Basic
-
1.23
3.21
Diluted
-
1.23
3.21
Weighted average shares outstanding
Basic
-
23,304
21,357
Diluted
-
23,304
21,357
EBITDA
-
-
-